SMAD2 and cancer: Additionally, other cancer-related genes were also mutated in our PMP preclinical models, such as the BRAF oncogene (7%); members of the TGF pathway, TGFBR2 (21%), SMAD2 (4%), and SMAD4 (11%); and the tumor suppressor gene TP53 (14%; Supplementary Table S5).